Live Breaking News & Updates on Paul Matteis|Page 11

Stay updated with breaking news from Paul matteis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Biogen's CEO Didn't Mention an Impending FDA Decision, Sending the Stock Down

Despite generally positive earnings and a cost-savings plan that will reduce the company’s head count by 1,000, shares of Biogen have traded down sharply. ....

Josh Nathan Kazis , Stifel Paul Matteis , Jefferie Michael Yee , Adam Glanzman Bloomberg , Christopher Viehbacher , Drug Administration , Sage Therapeutics , Michael Yee , Paul Matteis , Article Normal , Biotechnology Services , Anti Depressants , Healthcare Life Sciences , Specialized Drugs Medications , Regulation Government Policy , New Products Services , Product Service Approvals , Corporate Industrial News , Products Services , Senior Level Management , Political General News , Mood Disorders , Medical Conditions , Mental Disorders , Content Types , Factiva Filters ,

Biogen (BIIB) Q2 2023 Earnings Call Transcript

BIIB earnings call for the period ending June 30, 2023. ....

South Korea , United Kingdom , United States , Great Britain , Robyn Karnauskas , Chris Viehbacher , Salveen Richter Goldman Sachs , Robyn Karnauskas Truist , Susan Langer , Christopher Viehbacher , Priya Singhal , Brian Skorney , Salveen Richter , Chris Schott Jpmorgan , Lynn Kramer , Evan Seigerman , Samsung Bioepis , Paul Matteis , Fadia Needham , Mike Yee Jefferies , Michael Yee , Chris Schott , Mike Mcdonnell , Tim Anderson , Marc Goodman , Brian Abrahams ,

Roche buys into Alnylam heart drug in cardiovascular research bet

BioPharma ....

Yvonne Greenstreet , Paul Matteis , Bristol Myers Squibb , Merck Co , Alnylam Pharmaceuticals , Medicines Company ,

FDA's OK Isn't Always a Happy Day for Biotech Investors | Mint #AskBetterQuestions

Recent approvals of drugs, such as Biogen’s Leqembi, have left investors unimpressed ....

David Wainer , Paul Matteis , Eisai Leqembi , Reata Pharmaceuticals , Drug Administration , Biomarin Pharmaceutical , Sarepta Therapeutic Elevidys , Us Fda ,

Alzheimer's drug Leqembi sales may be slow at first: Analysts

Analysts believe the Medicare registry requirement and new guidance on Leqembi's prescription label could potentially weigh on sales in the near term. ....

Michael Yee , Marc Goodman , Yatin Suneja , Paul Matteis , Jefferie Yee , National Institute On , Drug Administration , National Institute , Biotech And Pharmaceuticals , Health Care Industry , Eisai Co Ltd , Biogen Inc , Social Issues , Alzheimer X27s Disease , Business News ,